Internal Medicine, Cardiovascular Disease · Omaha, NE
NPI
1023108701
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
Emile @ 42nd St
Omaha, NE, 68198
Phone (402) 559-8888
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
1,111 services
Medicare patients, 2024
289
Average age 71
Drug cost, 2024
$17.4M
5,064 prescriptions
Company payments, 2025
$167K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ronald Zolty was code 99215 (office e&m - established), 239 times for 166 patients. In total Ronald Zolty billed 1,111 services in 28 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 239 | 166 | $97.24 | $23K |
| 99291 Critical Care E&M | Facility | 157 | 33 | $150.25 | $24K |
| 93264 External Electrocardiographic Monitoring | Facility | 126 | 18 | $22.30 | $2,810 |
| 99232 Hospital E&M - Subsequent | Facility | 122 | 42 | $55.98 | $6,829 |
| 93750 External Electrocardiographic Monitoring | Facility | 85 | 18 | $26.78 | $2,276 |
| 99152 Anesthesia | Facility | 80 | 77 | $8.33 | $666 |
| 93451 Percutaneous Transcatheterization | Facility | 70 | 69 | $82.96 | $5,807 |
| 94618 Pulmonary Function Testing | Facility | 47 | 45 | $15.40 | $724 |
| 99223 Hospital E&M - Initial | Facility | 40 | 38 | $125.05 | $5,002 |
| 99233 Hospital E&M - Subsequent | Facility | 36 | 12 | $86.00 | $3,096 |
| 93464 Percutaneous Transcatheterization | Facility | 28 | 28 | $61.68 | $1,727 |
| 99239 Hospital Discharge Management | Facility | 23 | 18 | $83.03 | $1,910 |
| 99205 Office E&M - New | Facility | 14 | 14 | $121.37 | $1,699 |
By year: 2022 $98K for 1,146 services; 2023 $106K for 1,327 services; 2024 $85K for 1,111 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ronald Zolty prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 451 prescriptions and refills. In total Ronald Zolty wrote 5,064 Medicare prescriptions that cost $17.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 451 | 882 | 108 | $472K |
| Adempas Riociguat | 424 | 424 | 45 | $5.8M |
| Entresto Sacubitril/Valsartan | 346 | 620 | 82 | $376K |
| Spironolactone Generic | 340 | 820 | 102 | $1,995 |
| Sildenafil Citrate Generic | 263 | 347 | 51 | $50K |
| Metoprolol Succinate Generic | 241 | 626 | 72 | $3,078 |
| Uptravi Selexipag | 230 | 230 | 29 | $5.5M |
| Torsemide Generic | 185 | 413 | 64 | $5,241 |
| Ozempic Semaglutide | 169 | 197 | 29 | $162K |
| Potassium Chloride Generic | 147 | 295 | 39 | $4,317 |
| Atorvastatin Calcium Generic | 130 | 330 | 32 | $907 |
| Opsumit Macitentan | 117 | 117 | 15 | $1.5M |
| Furosemide Generic | 115 | 280 | 44 | $721 |
| Pantoprazole Sodium Generic | 113 | 280 | 31 | $1,084 |
| Eliquis Apixaban | 110 | 235 | 30 | $132K |
Brand drugs: - claims; generic drugs: 2,706 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ronald Zolty $167K ($167K in general payments such as food, travel and fees) from 11 companies. The largest payer was Merck Sharp & Dohme LLC with $46K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 44 | $46K |
| Alnylam Pharmaceuticals Inc. ALNY | 34 | $37K |
| Actelion Pharmaceuticals US, Inc. JNJ | 60 | $37K |
| United Therapeutics Corporation UTHR | 27 | $28K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $19K |
| Abbott Laboratories ABT | 7 | $206 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $53.1 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $44.22 |
| Analog Devices Inc. | 1 | $24.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.